Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 18/20 | 1.00 |
| ▸ | TACR3 | P29371 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880446 | 0.94 | GPBAR1 (1.00) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4874706 | 0.91 | GPBAR1 (1.00) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4880217 | 0.91 | GPBAR1 (0.86) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4873616 | 0.89 | GPBAR1 (0.80) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4740522 | 0.87 | GPBAR1 (0.83) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4741901 | 0.87 | GPBAR1 (0.76) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4871712 | 0.86 | GPBAR1 (0.76) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4739253 | 0.86 | GPBAR1 (0.82) | GPBAR1PDGFRBPDGFRA | |
| SCHEMBL4739893 | 0.86 | GPBAR1 (0.80) | GPBAR1 | |
| SCHEMBL4741402 | 0.84 | GPBAR1 (0.72) | GPBAR1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | GPBAR1 15/4885TACR3 985/4885PDGFRB 1990/4885 |
| US-20080221161-A1 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE | GPR119, GPBAR1, LDLR | GPBAR1 2/4885TACR3 407/4885PDGFRB 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.